Abstract
S-1090, a new oral cephalosporin, was active against selected gram-negative bacteria and methicillin-susceptible clinical isolates of Staphylococcus aureus, Staphylococcus epidermidis, and Staphylococcus warneri, against which it had excellent activity. S-1090 was the most active compound against Streptococcus pyogenes and Streptococcus agalactiae among the agents compared. The in vivo efficacy of S-1090 against systemic and urinary and respiratory tract infections caused by gram-positive and -negative bacteria was superior to that expected from the in vitro and in vivo activities of the agents against which it was compared.
Full Text
The Full Text of this article is available as a PDF (204.7 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Kamimura T., Kojo H., Matsumoto Y., Mine Y., Goto S., Kuwahara S. In vitro and in vivo antibacterial properties of FK 027, a new orally active cephem antibiotic. Antimicrob Agents Chemother. 1984 Jan;25(1):98–104. doi: 10.1128/aac.25.1.98. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kloos W. E., Bannerman T. L. Update on clinical significance of coagulase-negative staphylococci. Clin Microbiol Rev. 1994 Jan;7(1):117–140. doi: 10.1128/cmr.7.1.117. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Melegh B., Kerner J., Bieber L. L. Pivampicillin-promoted excretion of pivaloylcarnitine in humans. Biochem Pharmacol. 1987 Oct 15;36(20):3405–3409. doi: 10.1016/0006-2952(87)90318-2. [DOI] [PubMed] [Google Scholar]
- Miyazaki S., Miyazaki Y., Tsuji A., Nishida M., Goto S. In vitro antibacterial activity of ME1207, a new oral cephalosporin. Antimicrob Agents Chemother. 1991 Aug;35(8):1691–1694. doi: 10.1128/aac.35.8.1691. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Neu H. C., Saha G., Chin N. X. Comparative in vitro activity and beta-lactamase stability of FK482, a new oral cephalosporin. Antimicrob Agents Chemother. 1989 Oct;33(10):1795–1800. doi: 10.1128/aac.33.10.1795. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Nishino T., Maeda Y., Ohtsu E., Koizuka S., Nishihara T., Adachi H., Okamoto K., Ishiguro M. Studies on penem antibiotics. II. In vitro activity of SUN5555, a new oral penem. J Antibiot (Tokyo) 1989 Jun;42(6):977–988. doi: 10.7164/antibiotics.42.977. [DOI] [PubMed] [Google Scholar]
- Shimizu K., Saito A., Shimada J., Ohmichi M., Hiraga Y., Inamatsu T., Shimada K., Tanimura M., Fujita Y., Nishikawa T. Carnitine status and safety after administration of S-1108, a new oral cephem, to patients. Antimicrob Agents Chemother. 1993 May;37(5):1043–1049. doi: 10.1128/aac.37.5.1043. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Totsuka K., Shimizu K., Konishi M., Yamamoto S. Metabolism of S-1108, a new oral cephem antibiotic, and metabolic profiles of its metabolites in humans. Antimicrob Agents Chemother. 1992 Apr;36(4):757–761. doi: 10.1128/aac.36.4.757. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Utsui Y., Inoue M., Mitsuhashi S. In vitro and in vivo antibacterial activities of CS-807, a new oral cephalosporin. Antimicrob Agents Chemother. 1987 Jul;31(7):1085–1092. doi: 10.1128/aac.31.7.1085. [DOI] [PMC free article] [PubMed] [Google Scholar]